Previous 10 | Next 10 |
Arbutus Biopharma (NASDAQ: ABUS ) perks up 3% after hours in reaction to positive data from a Phase 1a/1b clinical trial evaluating HBV capsid inhibitor AB-506 in healthy volunteers and two cohorts with chronic hepatitis B virus (HBV) infection. More news on: Arbutus Biopharm...
Results demonstrate that AB-506 is a potent capsid inhibitor Phase 1a/1b clinical trial to continue with the enrollment of further cohorts Conference call and webcast scheduled today at 4:45 pm ET WARMINSTER, Pa., July 15, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporati...
Arbutus Biopharma (NASDAQ: ABUS ) has sold a part of its royalty interest in future global sales of Alnylam Pharmaceuticals' ONPATTRO (patisiran), approved by the U.S. and Europe in August 2018 for polyneuropathy caused by hATTR, to an Ontario, Canada-based pension plan called OMERS. Mor...
- Arbutus to receive $20 million in gross proceeds before advisory fees while retaining significant downstream economics - Runway extended with non-dilutive capital WARMINSTER, Pa., July 02, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an indust...
Gainers: Roan Resources (NYSE: ROAN ) +44% . Arbutus Biopharma Corporation (NASDAQ: ABUS ) +42% . China Internet Nationwide Financial Services (NASDAQ: CIFS ) +28% . DiaMedica Therapeutics (NASDAQ: DMAC ) +27% . B Communications (NASDAQ: BCOM ) +24% . Hebron Technology (NASDAQ: ...
Arbutus Biopharma (NASDAQ: ABUS ) has received regulatory clearance to initiate a Phase 1a/1b clinical trial of AB-729, a subcutaneously-administered RNA interference (RNAi) agent. More news on: Arbutus Biopharma Corporation, Healthcare stocks news, Stocks on the move, Read more ... ...
- AB-729 is a subcutaneously-administered RNAi agent targeting HBV replication and HBsAg antigen production - Supports corporate objective to combine AB-729 with AB-506, Arbutus’ proprietary oral capsid inhibitor WARMINSTER, Pa., June 20, 2019 (GLOBE NEWSWIRE) -- Arbutus Biop...
Gainers: Sotheby's (NYSE: BID ) +58% . Array BioPharma (NASDAQ: ARRY ) +57% . ContraVir Pharmaceuticals (NASDAQ: CTRV ) +42% . Vislink Technologies (NASDAQ: VISL ) +40% . MTech Acquisition (NASDAQ: MTEC ) +34% . Endurance International Group Holdings (NASDAQ: EIGI ) +26% . C&am...
Arbutus Biopharma (NASDAQ: ABUS ) appoints William H. Collier as President, Chief Executive Officer (CEO) and member of the Board of Directors, effective June 24. More news on: Arbutus Biopharma Corporation, Healthcare stocks news, Read more ...
WARMINSTER, Pa., June 17, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced the appointment of William H. Collier as President and Chief Executive Officer, effective June 24th. Mr...
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage bio...
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001 clinical trial show that AB-101 was generally well-tolerated and bound to the receptor tar...
WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepa...